# Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib

> **NCT00101660** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 387 (actual)

## Conditions studied

- Chronic Myeloid Leukemia
- Philadelphia-Positive Myeloid Leukemia

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT00101660
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2006-09
- **Final completion:** 2008-04
- **Target enrollment:** 387 (ACTUAL)
- **Last updated:** 2012-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00101660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00101660, "Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00101660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*